KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) Research & Development (2016 - 2025)

Rigel Pharmaceuticals has reported Research & Development over the past 16 years, most recently at $10.7 million for Q4 2025.

  • Quarterly results put Research & Development at $10.7 million for Q4 2025, up 89.72% from a year ago — trailing twelve months through Dec 2025 was $33.3 million (up 42.41% YoY), and the annual figure for FY2025 was $33.3 million, up 42.41%.
  • Research & Development for Q4 2025 was $10.7 million at Rigel Pharmaceuticals, up from $7.4 million in the prior quarter.
  • Over the last five years, Research & Development for RIGL hit a ceiling of $18.3 million in Q3 2021 and a floor of $2.5 million in Q4 2022.
  • Median Research & Development over the past 5 years was $7.9 million (2025), compared with a mean of $9.7 million.
  • Biggest five-year swings in Research & Development: tumbled 81.21% in 2022 and later surged 89.72% in 2025.
  • Rigel Pharmaceuticals' Research & Development stood at $13.3 million in 2021, then tumbled by 81.21% to $2.5 million in 2022, then increased by 27.44% to $3.2 million in 2023, then surged by 76.77% to $5.6 million in 2024, then surged by 89.72% to $10.7 million in 2025.
  • The last three reported values for Research & Development were $10.7 million (Q4 2025), $7.4 million (Q3 2025), and $6.8 million (Q2 2025) per Business Quant data.